Here’s a brief look at therapies for neurological disorders that the FDA has approved within the past 6 months.
Biogen and Sage Terminate Development of SAGE-324 Following Disappointing Phase 2 Data
Episode 119: Utilizing the Syn-One Test to Diagnose Parkinson Disease
Ionis to Advance ION582 in Phase 3 Studies of Angelman Syndrome Following Positive Open-Label Data
Episode 118: Gaining Patient Perspectives on the Impact of Narcolepsy
New FNIH Initiative Looks to Expedite Parkinson Disease Diagnosis Through Validated Biomarkers
Utility of Helius’ Neuromodulation System to Treat Gait in Multiple Sclerosis